FibroBiologics Announces Grant of European Patent for Methods of Enhancing Fibroblast Therapeutic Activity

The grant adds European patent coverage for methods linked to FibroBiologics' disc degeneration pathway.

Rhea-AI Summary

FibroBiologics (FBLG) received European Patent No. 3568465 for methods intended to enhance the regenerative activity of fibroblasts.

The granted claims cover preparing fibroblasts with platelet-rich plasma and one or more cytokines, including FGF-alpha or FGF-beta. They also cover combinations that include a TGF-beta-family cytokine. Additional claims address blood-vessel formation, known as angiogenesis, and spinal disc regeneration. FibroBiologics links the patent to its disc degeneration clinical pathway.

Positive

• Minor pointEuropean Patent No. 3568465 was granted for methods of enhancing fibroblast therapeutic activity.
• Minor pointAdditional granted claims cover angiogenesis and spinal disc regeneration.

Negative

• None.

Argus 15 min delay 2 alerts

+4.69% vs previous close $1.42 last price 9.7x rel. volume Open Argus

Details

Market move: FBLG +4.69% vs previous close. European patent grant

-12.0% Trough Tracked

$1.30 – $1.48 Day Range

$9.90M Market Cap

On Sep 29, the day this news came out, the latest delayed price for FBLG is 4.69% above the previous close. Argus tracked a trough of -12.0% from its starting point during tracking. Our momentum scanner has recorded 2 alerts for this stock so far that day. The latest delayed price is $1.42. Relative volume is exceptionally heavy at 9.7x the average.

Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.

Market Context

The Sep 01 U.S. patent record covered conditioned-media methods in the same disc-degeneration pathwa...

Analysis

The Sep 01 U.S. patent record covered conditioned-media methods in the same disc-degeneration pathway; FBLG’s pre-publication 24-hour move was +22.67%, a historical observation that does not establish a reaction to this distinct European patent.

Historical Context

1 past event · Latest: Sep 01

1 event

1. Sep 01

   U.S. disc patent

   24h Move

   +22.7%

   Granted U.S. claims for conditioned media targeting degenerative disc disease.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

platelet rich plasma, cytokines, angiogenesis, fibroblast growth factor alpha

4 terms

platelet rich plasma medical

"contacting the fibroblasts with platelet rich plasma"

A small volume of a patient’s own blood that has been processed to concentrate platelets—cells that release growth and repair signals—into a liquid used to speed healing when injected or applied to injured tissue. For investors, platelet rich plasma matters because it underpins a range of low‑risk, clinic‑based treatments in orthopedics, dermatology and aesthetics, where commercial success depends on demonstrated effectiveness, insurance coverage and regulatory acceptance.

cytokines medical

"with platelet rich plasma and one or more cytokines"

Small proteins produced by immune and other cells that act as on/off signals or “text messages,” telling cells to ramp up, calm down, grow, or move during infection, injury, or disease. Investors watch cytokines because they are common drug targets and biomarkers—changes in cytokine activity can make a therapy work, cause serious side effects, or determine clinical trial and regulatory outcomes, all of which affect a company’s value.

angiogenesis medical

"additional claims directed to angiogenesis"

Angiogenesis is the biological process where the body builds new blood vessels, like laying new roads to deliver oxygen and nutrients to tissues. Investors care because many drugs aim to block or encourage this process to treat cancer, eye diseases, or chronic wounds; success or failure in controlling angiogenesis often determines a therapy’s effectiveness, regulatory approval, safety profile, and commercial potential.

fibroblast growth factor alpha medical

"including fibroblast growth factor alpha (FGF-alpha)"

A protein name used for a member of the fibroblast growth factor (FGF) family that sends signals telling cells to grow, divide, move, or form blood vessels; these signals play roles in development, wound healing, and tissue repair. It matters to investors because FGFs are often the biological targets or active ingredients in drugs and diagnostics, so discoveries, trial results, or regulatory news about them can affect a biotech company's clinical progress and commercial value — like news about a key ingredient in a product pipeline.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Newly Granted Patent Covers Methods of Augmenting the Regenerative Efficacy of Fibroblasts Using Platelet Rich Plasma and Cytokines, with Claims Directed to Angiogenesis and Spinal Disc Regeneration

HOUSTON, Sept. 29, 2026 /PRNewswire/ -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics" or the "Company"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that the European Patent Office has granted European Patent No. 3568465, titled "Methods of Enhancing Fibroblast Therapeutic Activity." The patent covers methods of augmenting the efficacy of fibroblasts for the regeneration of cells and/or tissues by contacting the fibroblasts with platelet rich plasma and one or more cytokines, including fibroblast growth factor alpha (FGF-alpha) or fibroblast growth factor beta (FGF-beta), with additional claims directed to angiogenesis and the regeneration of spinal discs.

Chronic lower back pain is one of the most common and costly medical conditions, and degeneration of the intervertebral discs is a frequent underlying cause. As described in the patent, lower back pain affects approximately 80% of Americans at some point in their lives. As a disc degenerates, it loses proteoglycans and water content, the composition of its collagen changes, and inflammatory processes set in, all of which contribute to pain and loss of function. Most available treatments manage symptoms or rely on surgery rather than restoring the disc tissue itself. The methods described in the patent are designed to condition fibroblasts with platelet rich plasma and specific cytokines so that the cells possess enhanced anti-inflammatory, angiogenic, and regenerative properties, including an increased capacity to produce proteoglycans and matrix, before they are used to treat degenerated tissue.

Key highlights of the granted claims include:

• A method of augmenting the efficacy of fibroblasts for the regeneration of cells and/or tissues by contacting the fibroblasts with platelet rich plasma and one or more cytokines, wherein the cytokines comprise FGF-alpha or FGF-beta, with additional coverage of cytokine combinations that further comprise a member of the TGF-beta family;
  
  
• Application of the enhanced fibroblasts to regeneration involving angiogenesis and to the regeneration of spinal discs, supporting the Company's disc degeneration clinical pathway; and
  
  
• Broad coverage of the fibroblasts themselves and how they are delivered, including fibroblasts obtained by biopsy and expanded in culture, subsets with a greater ability to differentiate,  fibroblasts derived from skin, heart, blood vessels, bone marrow, skeletal muscle, liver, pancreas, brain, adipose tissue, foreskin, or adult origin, and delivery in pharmaceutically acceptable carriers such as sterile solutions, hydrogels, implantable cell matrices, and devices.

"Fibroblasts are remarkable cells, but how they perform in the body depends a great deal on how they are prepared before they get there," said Pete O'Heeron, Founder and Chief Executive Officer of FibroBiologics, and an inventor on the patent. "This patent protects a simple idea with important consequences. By exposing fibroblasts to platelet rich plasma and specific growth factors, we can send cells into damaged tissue that are primed to build new matrix, support blood vessel formation, and reduce inflammation. Disc degeneration has resisted biological treatment for decades, and securing these claims in Europe strengthens the global protection around our disc program and around our broader fibroblast platform."

The patent adds to FibroBiologics' broad portfolio of issued and pending patents covering fibroblast-based therapies across multiple chronic disease areas, including its disc degeneration clinical pathway.

For more information, please visit FibroBiologics' website, email FibroBiologics at info@fibrobiologics.com or follow FibroBiologics on LinkedIn, YouTube, Facebook or X.

About FibroBiologics

Based in Houston, FibroBiologics is a clinical-stage biotechnology company developing a pipeline of treatments and seeking potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. FibroBiologics holds 270+ US and internationally issued patents/patents pending across various clinical pathways, including wound healing, multiple sclerosis, disc degeneration, psoriasis, orthopedics, human longevity, and cancer. FibroBiologics represents the next generation of medical advancement in cell therapy and tissue regeneration. For more information, visit www.FibroBiologics.com.

Cautionary Statement Regarding Forward-Looking Statements

This communication contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements include information concerning the scope and strength of the Company's intellectual property portfolio, the potential indications for FibroBiologics' programs, FibroBiologics' research and development programs, and the potential clinical benefits of fibroblasts and fibroblast-derived materials. These forward-looking statements are based on FibroBiologics' management's current expectations, estimates, projections and beliefs, as well as a number of assumptions concerning future events. These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside FibroBiologics' management's control, that could cause actual results to differ materially from the results discussed in the forward-looking statements, including those set forth under the caption "Risk Factors" and elsewhere in FibroBiologics' annual, quarterly and current reports (i.e., Form 10-K, Form 10-Q and Form 8-K) as filed or furnished with the SEC and any subsequent public filings. Copies are available on the SEC's website, www.sec.gov. These risks, uncertainties, assumptions and other important factors include, but are not limited to: (a) risks related to FibroBiologics' liquidity and its ability to maintain capital resources sufficient to conduct its business; (b) expectations regarding the initiation, progress and expected results of FibroBiologics' R&D efforts and preclinical studies; (c) the unpredictable relationship between R&D and preclinical results and clinical study results; and (d) the ability of FibroBiologics to successfully prosecute its patent applications. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and FibroBiologics assumes no obligation and, except as required by law, does not intend to update, or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. FibroBiologics gives no assurance that it will achieve its expectations.

General Inquiries:
info@fibrobiologics.com

Investor Relations:
Nic Johnson
Russo Partners
(212) 845-4242
fibrobiologicsIR@russopr.com

Media Contact:
Liz Phillips
Russo Partners
(347) 956-7697
Elizabeth.phillips@russopartnersllc.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/fibrobiologics-announces-grant-of-european-patent-for-methods-of-enhancing-fibroblast-therapeutic-activity-302892133.html

SOURCE FibroBiologics, Inc.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does FibroBiologics' new European patent cover?

The patent covers methods of preparing fibroblasts with platelet-rich plasma and one or more cytokines, including FGF-alpha or FGF-beta, to enhance their regenerative activity. Its claims also cover combinations with a TGF-beta-family cytokine, angiogenesis and spinal disc regeneration.